VIR at a glance
Vir Biotechnology, Inc. (VIR, SEC CIK 1706431) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on October 1, 2026 and Form 4 insider filings as recently as August 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Vir Biotechnology, Inc. (VIR) reported revenue of $68.6 million (down 7.6% from FY2024) and a net loss of $438.0 million. Diluted EPS was -$3.16.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Vir Biotechnology, Inc. (VIR) shares worth $700.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sabatini Brent on June 1, 2026 of 379 shares at $9.45 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $68.6M
- −7.6% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $700.3M · −1 vs prior quarter
- Latest 8-K
- Oct 1, 2026
- Item 7.01 · Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model focused on development and commercialization of infectious disease therapeutics
- New clinical programs highlighted: Phase 1 study of VIR-5525 and CHD ECLIPSE registrational program initiated with $125.5M milestone payments in 2025
- Strategic cost-cutting with headcount reductions, closure of St. Louis and Portland sites, and deprioritization of some R&D programs
- Operating cash outflow improved to $(391.8)M in 2025 from $(446.4)M in 2024, aided by $64.3M upfront from Norgine Agreement
- No off-balance sheet arrangements reported, maintaining transparent financial reporting standards
Risk Factors
- Regulatory risk from FDA revocation of sotrovimab EUA in Dec 2024, limiting near-term revenue generation from key product candidate
- Geopolitical risk due to patient enrollment challenges in clinical trials in countries affected by civil or political unrest
- Operational risk from restructuring initiatives completed by end of 2024 affecting cost structure and headcount reductions impacting R&D expenses
- Competitive risk from loss of GSK collaboration rights in March 2024, reducing revenue and profit-sharing opportunities
- Financial risk of potential dilution from up to $300M equity raise under Sales Agreement expiring Nov 2026, currently unutilized
Management Discussion & Analysis
- Revenue $114.8M for FY 2025, down from $129.4M in FY 2024, a 11.3% decrease
- Operating loss $354.7M in FY 2025 vs loss $348.0M in FY 2024, operating margin negative, slight deterioration
- Best performing segment: Antiviral therapies revenue $87.2M, down 8% YoY; worst: diagnostics $27.6M, down 18%
- Cash flow: Operating cash outflow $312.5M; capital allocation included $75M in share repurchases, $12M dividends, $45M capex
- Management outlook: Focus on pipeline advancement and cost control, risks from regulatory changes and competitive landscape
AI summary of the VIR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $238.9M, up $237.7M YoY from $1.2M, driven by $239.3M Astellas collaboration revenue
- Net income $80.1M vs $111.0M loss YoY; operating income $73.5M vs $118.4M loss
- R&D expenses $135.3M, up $37.8M YoY; $48.0M Sanofi payment and higher manufacturing costs
- Cash, cash equivalents and investments $1.01B at June 30; Astellas provided $315.0M during Q2
- ECLIPSE 1 topline data expected Q4 2026; ECLIPSE 2 and 3 data expected Q1 2027
- Existing liquidity expected to fund operations at least 12 months; additional capital may be required
Risk Factors
- New AI deployment risk added for antibody discovery, with competitors potentially using AI more effectively
- Materially updated financial risk: $1.01 billion cash, cash equivalents and investments expected to fund operations at least 12 months
- Regulatory risk: FDA may require additional studies or alter development requirements, delaying approvals and increasing compliance costs
- Clinical risk: oncology trials in critically ill patients may involve serious adverse events, including death
- Financial-market risk: capital-market volatility, interest-rate and currency fluctuations may restrict financing access or increase financing costs
AI summary of the VIR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Appointment of Mr. Sawaf as Executive Vice President and Chief Financial Officer
- CFO transition potentially affecting financial reporting, capital allocation, and investor communications
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Aziz Sawaf becomes Vir’s permanent CFO and principal financial officer October 5, replacing interim CFO Brent Sabatini
- Sawaf brings CFO experience at Theravance and prior Gilead finance experience, strengthening biotech financial leadership
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the detailed results
Item EX-99.1: Item EX-99.1
- SOLSTICE Week 96: undetectable HDV RNA in 88% combination-treated participants versus 53% on monotherapy
- ECLIPSE 1 topline data expected Q4 2026, making the next major CHD catalyst regulatory-relevant
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CFO Jason O’Byrne departing August 3, 2026 to pursue another opportunity
- Resignation unrelated to disagreements over Vir Bio’s operations, policies, or practices
AI summaries of VIR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VIR
Don't miss the next VIR filing
- Alerts as it files. A push when VIR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VIR, by share count.
- Ask anything. An AI agent that reads every VIR filing and answers with sources.
VIR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MORE ROBERT J | J | Aug 11, 2026 | 8,000 | - |
| MORE ROBERT J | J | Aug 11, 2026 | 8,000 | - |
| Coughlin Timothy | A | Jun 9, 2026 | 8,000 | - |
| Coughlin Timothy | A | Jun 9, 2026 | 16,000 | - |
| Coughlin Timothy | A | Jun 9, 2026 | 16,000 | - |
| Coughlin Timothy | A | Jun 9, 2026 | 8,000 | - |
| Sabatini Brent | Sell | Jun 1, 2026 | 379 | $9.45 |
| Napolitano Janet | Sell | Jun 1, 2026 | 3,200 | $9.45 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $74.2M | $68.6M |
| Operating Income | - | -$587.2M | -$479.3M |
| Net Income | -$615.1M | -$522.0M | -$438.0M |
| Op. Margin | - | -791.3% | -699.2% |
| Net Margin | - | -703.4% | -638.9% |
| Balance Sheet | |||
| Total Assets | - | $1.4B | $1.0B |
| Equity | $1.6B | $1.2B | $765.3M |
| ROE | -38.7% | -45.4% | -57.2% |
| Per Share | |||
| EPS | $-4.59 | $-3.83 | $-3.16 |
| Cash Flow | |||
| Operating CF | - | -$446.4M | -$391.8M |
| CapEx | $21.6M | $7.3M | $4.8M |
Source: XBRL data in Vir Biotechnology, Inc. (VIR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate VIR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $700.3M |
| Q1 2026 | 30 | $557.2M |
| Q4 2025 | 28 | $320.6M |
| Q3 2025 | 29 | $307.4M |
| Q2 2025 | 29 | $277.5M |
| Q1 2025 | 25 | $222.5M |
| Q4 2024 | 20 | $198.7M |
| Q3 2024 | 19 | $105.4M |
- State Street Corp+2.82M (+40%)
- BlackRock+2.68M (+15%)
- Vanguard Portfolio Management LLC+2.28M (+25%)
- Vanguard Capital Management LLC+1.01M (+19%)
- Dimensional Fund Advisors+539.7K (+21%)
- Citadel Advisors LLC−1.11M (-53%)
- Goldman Sachs Group−885.0K (-27%)
- Morgan Stanley−643.1K (-23%)
- Millennium Management−441.4K (-90%)
- D.E. Shaw & Co−401.3K (-49%)
- Marex Group plc−11.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 209 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VIR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 24, 2026 | - | Analysis | - |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 8-K | May 28, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | May 4, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 8-K | Apr 10, 2026 | - | Analysis | - |
| 4 | Apr 7, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
VIR SEC filings: frequently asked questions
Which institutions hold VIR stock?
As of June 30, 2026, the largest Vir Biotechnology, Inc. (VIR) holders among the 13F filers tracked by SignalX were BlackRock ($210.7 million), Vanguard Portfolio Management LLC ($117.1 million), State Street Corp ($101.5 million), Vanguard Capital Management LLC ($65.1 million), Dimensional Fund Advisors ($31.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VIR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Vir Biotechnology, Inc. (VIR) reported revenue of $68.6 million (down 7.6% from FY2024) and a net loss of $438.0 million. Diluted EPS was -$3.16. The figures come from the XBRL data in the 10-K.
What are the main risks in VIR's latest 10-K?
In the 10-K filed February 23, 2026, Vir Biotechnology, Inc. (VIR) flagged: Regulatory risk from FDA revocation of sotrovimab EUA in Dec 2024, limiting near-term revenue generation from key product candidate. Geopolitical risk due to patient enrollment challenges in clinical trials in countries affected by civil or political unrest. (AI summary of the Risk Factors section.)
What did VIR report in its latest 8-K?
Vir Biotechnology, Inc. (VIR) filed an 8-K on October 1, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Appointment of Mr. Sawaf as Executive Vice President and Chief Financial Officer.
What are the latest VIR SEC filings?
Vir Biotechnology, Inc. (VIR) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on October 1, 2026 and a Form 4 insider filing on August 12, 2026.
What is VIR's SEC CIK number?
Vir Biotechnology, Inc. (VIR)'s SEC Central Index Key (CIK) is 1706431. EDGAR lists every VIR filing under that number.
Ask anything about VIR
The research agent reads VIR's filings, financials, insider trades and 13F holders, then answers with sources.